APA (7th ed.) Citation

Wang, Y. C., Sandrock, A., Richert, J. R., Meyerson, L., & Miao, X. Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab. Wiley.

Chicago Style (17th ed.) Citation

Wang, Y. C., A. Sandrock, J. R. Richert, L. Meyerson, and X. Miao. Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab. Wiley.

MLA (9th ed.) Citation

Wang, Y. C., et al. Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab. Wiley.